metastatic urothelial carcinoma in adults, for whomcisplatin-based chemotherpay is unsuitable, | only if conditions of the managed access agreement are followed. (NHS England Cancer Drugs Fund) | RED Alectinib recommended as an option for untreated anaplastic lymphoma kinase (ALK)-positive advanced | non-small-cell cancer in adults - as per NICE TA536 (NHS England Commissioned) | RED Arsenic trioxide is recommended, within its marketing authorisation, as an option for inducing remission | and consolidation in acute promyelocytic leukaemia as per NICE TA526 (NHS England Commissioned) | | RED Atezolizumab - for use within the Cancer Drugs Fund as an option for untreated locally advanced or | metastatic urothelial carcinoma in adults, for whom cisplatin-based chemotherpay is unsuitable , only if | conditions of the managed access agreement are followed as per NICE TA492 | | (Guidance updated July 2018: The European medicines Agency restricted the use of Atezolizumab for untreated urothelial carcinoma. It should now only be used in adults with high levels of PD-L1. For more information, see | thesummary of product characteristics for atezolizumab. (NHS England Cancer Drugs Fund) | | RED Atezolizumab - for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy. recommended as an option in NICE TA520 in adults who have had chemotherapy (and targeted treatment if | they have an EGFR- or ALK‑positive tumour), only if: | > atezolizumab is stopped at 2 years of uninterrupted treatment or earlier if the disease progresses and | > the company provides atezolizumab with the discount agreed in the patient access scheme. | (NHS England Commissioned) | RED Atezolizumab - for treating locally advanced or metastatic urothelial carcinoma after platinum-containing | | chemotherapy. Recommended as an option in NICE TA525 only if: | > atezolizumab is stopped at 2 years of interrupted treatment or earlier if the disease progresses and | > the company provides atezolizumab with discount agreed in the patient access scheme | (NHS England Commissioned) | RED Atezolizumab plus bevacizumab, carboplatin and paclitaxel is recommended as an option for metastatic | non-squamous non-small-cell lung cancer (NSCLC) in adults, NICE TA584 | > who have not had treatment for their metastatic NSCLC before and whose PD-L1 tumour | proportion score is between 0% and 49% or | > when targeted therapy for epidermal growth factor receptor (EGFR)‑positive or anaplastic | lymphoma kinase (ALK)‑positive NSCLC has failed. | It is recommended only if: | > atezolizumab and bevacizumab are stopped at 2 years of uninterrupted treatment, or earlier if | there is loss of clinical benefit (for atezolizumab) or if the disease progresses (for bevacizumab) and | > the company provides atezolizumab and bevacizumab according to the commercial arrangements. | | NICE TA638 Atezolizumab with carboplatin and etoposide is recommended as an option for untreated extensive-stage | lung cancer in adults, only if: | > they have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and | > the company provides atezolizumab according to the commercial arrangement | (NHS England Commissioned) | NICE TA639 Atezolizumab with nab-paclitaxel is recommended, within its marketing authorisation, for treating triple | negative, unresectable, PD-L1-positive, locally advanced or metastatic breast cancer in adults whose | tumours express PD-L1 at a level of 1% or more and who have not had previous chemotherapy for | metastatic disease. It is recommended only if the company provides atezolizumab according to the | commercial arrangement. (NHS England Commissioned) |
NICE TA666 Atezolizumab plus bevacizumab is recommended as an option for treating advanced or unresectable |
hepatocellular carcinoma [HCC] in adults who have not had previous systemic treatment, only if: |
> they have Child-Pugh grade liver impairment and an Eastern Cooperative Oncology Group [ECOG] |
performance status of 0 or 1 and |
> the company provides it according to the commercial arrangement |
(NHS England Commissioned)
|
|
RED Axicabtagene ciloleucel therapy | NICE TA559 for use within the Cancer Drugs Fund as an option for treating relapsed or refractory diffuse large B‑cell | lymphoma or primary mediastinal large B‑cell lymphoma in adults after 2 or more systemic therapies, | only if the conditions in the managed access agreement are followed. (NHS England Cancer Drugs Fund) | | | | | |
RED Axitinib tablets 1mg, 3mg, 5mg, 7mg as per NICE TA333 |
RED Bortezomib injection 3.5mg in line with NICE TA311 |
RED Bortezomib injection 3.5mg for previously untreated mantle cell lymphoma in line with NICE TA370 |
RED Bosutinib tablets 100mg, 500mg recommended as an option, by NICE TA401 within its marketing authorisation, for chronic accelerated and blast phase Philadelphia chromosome positive chronic myeloid |
leukaemia in adults, when: |
> they have previously had 1 or more tyrosine kinase inhibitor and |
> imatinib, nilotinib and dasatinib are not appropriate and |
> the company provides bosutinib with the discount agreed in the patient access scheme |
(as revised in 2016) |
| RED Brentuximab vedotin (Adcetris®) | NICE TA524 Recommended as an option for treating CD30- positive Hodgkin Lymphoma in adults with relapsed or | refractory disease only as specified in NICE TA524 | [This guidance is a Cancer Drugs Fund reconsideration of NICE TA446 and replaces TA446] (NHS England Cancer Drugs Fund) | | NICE TA478 Recommended as an option for treating relapsed or refractory systemic anapplastic large cell | lymphoma in adults (NHS England Commissioned) | | NICE TA577 Recommended as an option for treating CD30-positive cutaneous T-cell lymphoma (CTCL) after at least 1 | systemic therapy in adults, only if: | > they have mycosis fungoides stage IIB or over, primary cutaneous anaplastic large cell lymphoma or Sézary | syndrome and | > the company prvides brentuximab vedotin according to the commercial arrangement | | NICE TA641 Recommended within its marketing authorisation, with cyclophosphamide, doxorubicin and prednisolone, | as an option for untreated systemic anaplastic large cell lymphoma in adults. | | (NHS England Commissioned) | | RED Brigatinib (Alunbrig) | NICE TA571 Recommended, within its marketing authoristaion, for treating anaplastic lymphoma kinase (ALK)-positive | advanced non-small-cell lung cancer in adults who have already had crizotinib, It is recommended only if | the company provides it according to the commercial arrangement. (NHS England Commissioned) | | | | |
RED Cabazitaxel in combination with prednisone or prednisolone is recommended an option for treating |
metastatic hormone-relapsed prostate cancer in people whose disease has progressed during or after |
docetaxel chemotherapy in NICE TA391 |
RED Cabozantinib as an option for treating advanced renal cell carcinoma in adults after vascular endothelial | growth factor-targeted therapy as per NICE TA463 (NHS England Commissioned) | RED Cabozanitinib recommended , within its marketing authorisation, as an option for treating progressive | medullary thyroid cancer in adults with unresectable, locally advanced or metastatic disease as | per NICE TA516 (NHS England Cancer Drugs Fund) | RED Cabozantinib is recommended, within its marketing authorisation, for adults with untreated advanced renal | cell carcinoma that is intermediate - or poor- risk as defined in the International Metaststaic Renal Cell | Carcinoma Database Consortium criteria - as in NICE TA542 (NHS England Commissioned) | | |
RED Carboplatin injection 150mg/15mL, 450mg/45mL |
RED Carfilzomib powder For solution for infusion NICE TA657 updates and replaces NICE TA457 |
RED Ceritinib capsules 150mg for previously treated anaplastic lymphoma kinase positive non-small-cell lung |
cancer as per NICE TA395 |
RED Ceritininb - within its marketing authorisation, is recommended as an option for untreated ALK-positive | non-small-cell lung cancer - NICE TA500 (NHS England Commissioned) | RED Ceritininb - within its marketing authorisation, is recommended as an option for untreated ALK-positive | non-small-cell lung cancer - NICE TA500 (NHS England Commissioned) | | | | |
RED Cetuximab infusion 5mg/mL |
RED Cetuximab is recommended, as an option for previously untreated metastatic colorectal cancer as per | NICE TA 439 (updated Sept 2017) | |
RED Cetuximab in combination with platinum based chemotherapy is recommended as an option for treating | recurrent or metastatic squamous cell cancer of the head and neck in adults only as per NICE TA473 | (NHS England Commissioned) | |
RED Cisplatin injection 50mg |
RED Crizotininb capsules 200mg, 250mg NICE TA406 (NHS England Commissioned) |
RED Crizotininb capsules 200mg, 250mg an option in previously treated anaplastic lymphoma kinase-positive |
advanced non-small-cell lung cancer in adults as per NICE TA422 |
RED Crizotinib is recommended for use within the Cancer Drugs Fund as an option for treating ROS1- positive | advancednon-small-cell lung cancer in adults only if the conditions in the managed access agreement are | followed - NICE TA529 (NHS England Cancer Drugs Fund) | |
RED Dabrafenib Capsules, 50 mg, 75 mg NICE TAG 321 |
RED Dabrafenib with trametinib is recommended, within its marketing authorisation, an option for the adjuvant | treatment of resected stage III BRAF V600 mutation-positivemelanoma in adults as per NICE TA544 | |
(NHS England Commissioned) |
RED Daratumumab monotherapy for treating relapsed and refractory multiple myeloma as per NICE TA510 |
|
RED Dasatinib tablets 20mg, 50mg, 80mg, 100mg,140mg option in treating only chronic- or accelerated-phase |
Philadelphia-chromosome-positive chronic myeloid leukaemia in adults as per NICE TA425 |
Replaces NICE TA241 (NHS England Commissioned) |
RED Dasatinib tablets 20mg, 50mg, 80mg, 100mg,140mg as an option for untreated chronic-phase Philadelphia- |
chromosome-positive chronic myeloid leukaemia in adults as per NICE TA426. Replaces NICE TA251 |
(NHS England Commissioned) |
RED Dacarbazine injection 1g |
RED Dinutuximab beta - is recommended as an option for treatin g high-risk neuroblastoma in people aged 12 | months and over whose disease has at least partially responded to induction chemotherapy, followed by | myeloablative therapy and stem cell transplant - as per NICE TA538 (NHS England Commissioned) | |
RED Docetaxel injection 20mg/0.5ml, 80mg/2ml (NICE indications only) |
RED Encorafenib with binimetinib - recommended, within its marketing authorisation, as an option for treating | unresectable or metastatic BRAF V600 mutation-positive melanoma in adults as per NICE TA562 | (NHS England Cancer Drugs Fund) | RED Entrectinib [Rozlytek] | NICE TA643 Recommended within its marketing authorisation, as an option for treating ROS1-positive advanced non- | small-cell lung cancer in adults who have not had ROS1 (NHS England Commissioned) | NICE TA644 Recommended for use within the Cancer Drugs Fund as an option for treating neurotropic tyrosine | receptor kinase [NTRK] fusion-positive solid tumours in adults and children 12 years and older if; | > the disease is locally advanced or metastatic or surgery could cause severe health problems and | > they have not had and NTRK inhibitor before and | > they have no satisfactory treatment options (Cancer Drugs Fund) | | |
RED Eribulin solution for injection 0.8mg/2ml, 1.32mg/3ml. An option in treating locally advanced or metastatic |
breast cancer in adults who have had 2 or more courses of chemotherapy as per NICE TA423 |
(replaces NICE TA250) (NHS England Commissioned) |
RED Erlotinib tablets 25mg, 100mg, 150mg (NICE indication only) |
RED Erlotinib tablets 25mg, 100mg, 150mg - treating non-small-cell lung cancer that has progressed after |
prior chemotherapy - NICE TA374 |
RED Everolimus 2.5mg, 5mg, 10mg tablets, in combination with exemestane is recommended as an option for treating advanced breast cancer after endocrine therapy - NICE TA421 (NHS England Commissioned) RED Everolimus tablets 2.5mg, 5mg, 10mg recommended as an option for treating advanced renal cell | carcinoma that has progressed during or after treatment with vascular endothelial growth factor targeted | therapy, only if the company provides it with the discount agreed in the patient access scheme. NICE TA432 | (NHS England Commissioned) RED Everolimus tablets 2.5mg, 5mg, 10mg recommended as an option treating well- or moderatley | differentiated unresectable or metastatic neuroendocrine tumours (NETs) of pancreatic origin | in adults with progressive disease. NICE TA 449 (NHS England Commissioned) | | RED Gilteritinib [Xospata] 40mg tablets | NICE TA642 recommended as an option for treating relapsed or refractory FLY3-mutation-positive acute myeloid | leukaemia in adults only if the company provides gilteritinib according to the commercial arrangement. | (NHS England Commissioned) | | | | |
RED Hydroxycarbamide capsules 500mg |
AMBER Hydroxycarbamide capsules 500mg - unlicensed use for psoriasis in adults. Specialist initiation only. | See Drug Monitoring in Primary Care for monitoring requirements | |
RED Gefitinib tablets 250mg as per NICE TA192 |
RED Gemtuzumab oxogamicin, with daunorubicin and cytarabine is recommended as an option for untreated | de novo CD33-positive acute myeloid leukaemia in people aged 15 years and over - as in NICE TA545 | (NHS England Commissioned) | |
RED Ibrutinib is recommended as an option for treating relapsed or refractory mantle cell lymphoma in adults only if they have had 1 previous line of therapy and the company provides ibrutinib with the agreed discount in the commercial access agreement with NHS England as in NICE TA502 | (NHS England Commissioned) | RED Ibrutinib capsules 140mg as an option for treating chronic lymphocytic leukaemia in adults who have had at | least 1prior therapy or, who have a 17p deletion or TP53 mutation, and in whom chemotherapy is | | | |
RED Idelalisib (Zydelig®) tablets 100mg, 150mg - as an option in NICE TA359 for treating chronic |
lymphocytic leukaemia |
RED Imatinib tablets 100mg, 400mg (NICE TAG326) |
RED Imatinib tablets 100mg, 400mg option in treating only chronic- or accelerated-phase |
Philadelphia-chromosome-positive chronic myeloid leukaemia in adults as per NICE TA425 |
Replaces NICE TA241 (NHS England Commissioned) |
RED Imatinib tablets 100mg, 400mg is recommended as an option for untreated, chronic-phase Philadelphia- |
chromosome-positive chronic myeloid leukaemia in adults. NICE TA426 (Replaces NICE TA251) |
RED Ipilimumab IV infusion 5mg/mL (NICE indications only as below) |
NICE TAG319 - as an possible treatment in previously untreated advanced (unresectable or metastatic) melanoma |
NICE TA268 as a possible treatment for people with previously treated advanced (unresectable or metastatic) melanoma |
RED Irinotecan concentrate for infusion 20mg/mL (NICE indication only) |
|
| RED Isatuximab [Sarclisa®] | NICE TA658 Isatuximab plus pomalidomide and dexamethasone is recommended for use within the Cancer Drugs | fund, as an option for treating relapsed and refractory multiple myeloma in adults who have had | lenalidomide and a proteasome inhibitor, and whose disease has progressed on their last treatment, only | if: | > they have had 3 previous lines of treatment | > the conditions in the managed access agreement for isatuximab plus pomalidomide and | dexamethasone are followed. (NHS England Commissioned) | |
RED Ixazomib |
NICE TA505 with lenalinomide and dexamethasone an option for use within the Cancer Drugs Fund for the treatment |
of relapsed or refractory multiple myeloma in adults |
(NHS England Commissioned) | RED Larotrectinib | NICE TA630 Recommended for use within the Cancer Drugs Fund as an option for treating neurotrophic tyrosine | receptor kinase (NTRK) fusion-positive solid tumours in adults and children if: | > the disease is locally advanced or metastatic or surgery could cause severe health problems and | > they have no satisfactory treatment options | It is recommended only if the conditions in the managed access agreement for larotrectinib are followed | | | NICE TA551 Recommended as an option for untreated, advanced, unresectable hepatocellular carcinoma in adults | (NHS England Commissioned) | NICE TA498 Recommended as an option with everolimus for previously treated advanced renal cell carcinoma | |
(NHS England Commissioned) | NICE TA535 And sorafenib are recommended as options for treating progressive, locally advanced or metastatic | | differentiated thyroid cancer (papillary, follicular or Hurthle cell) in adults whose disease does not respond | to radioactive iodine. (NHS England Commissioned) | | RED Lorlatinib tablets 25mg, (NHS England Commissioned) | NICE TA628 recommended, within its marketing authorisation, as an option for treating anaplastic lymphoma kinase | (ALK) - positive advanced small-cell lung cancer in adults whose disease has progressed after: | > alectinib or ceritinib as the first ALK tyrosine kinase inhibitor or | > crizotinib and at least 1 other ALK tyrosine kinase inhibitor | | RED Lutetium (177Lu) oxodotreotide | NICE TA539 Recommended as an option for treating unresectable or metastatic, progressive, well-differentiated | (grade 1 or grade 2) , somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours in | adults (NHS England Commissioned) | | RED Neratinib tablets 40mg (Nerlynx) | NICE TA612 Neratinib is recommended as an option for the extended adjuvant treatment of hormone receptor- | positive,human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer in adults | who completed adjuvant trastuzumab-based therapy less than 1 year ago only if: | > trastuzumab is the only HER2‑directed adjuvant treatment they have had, and | > if they had neoadjuvant chemotherapy-based regimens, they still had residual invasive disease in the | breast oraxilla following the neoadjuvant treatment, and | > the company provides neratinib according to the commercial arrangement. | | (NHS England Cancer Drug Fund) | | |
RED Nilotinib capsules 150mg, 200mg as an option for untreated chronic-phase Philadelphia-chromosome- positive chronic myeloid leukaemia in adults as per NICE TA426 (Replaces NICE TA251) |
(NHS England Commissioned) |
RED Nilotinib capsules 150mg, 200mg option in treating only chronic- or accelerated-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults as per NICE TA425 | Replaces NICE TA241 (NHS England Commissioned) | RED Niraparib - recommended for use within the cancer drugs fund as an option for treating relapsed, platinum- | sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer - as per | NICE TA528 (NHS England Cancer Drug Fund) | | | |
RED Nivolumab intravenous infusion 10mg/ml is recommended as an option by NICE for treating advanced |
(unresectable or metastatic) melanoma. NICE TA384 |
RED Nivolumab in combination with ipilimumab is recommended, within its marketing authorisation, as an |
option for treating advanced (unresectable or metastatic) melanoma in adults, only when the company |
provides ipilimumab with the discount agreed in the patient access scheme. NICE TA400. |
RED Nivolumab is recommended as an option for previously treated advanced renal cell carcinoma in adults. |
NICE TA417. (NHS England Commissioned) |
(updated September 2017 after a change to the commercial arrangements) |
RED Nivolumab is recommended as an option for treating relapsed or refractory classical Hodgkin lymphoma | in adults after autologous stem cell transplant and treatment with brentuximab vedotin as per NICE TA462 | (updated September 2017 after a change to the commercial arrangements) | RED Nivolumab is recommended for use within the Cancer Drugs Fund as an option for the adjuvant treatment | of completely resected melanoma in adults with lymph node involvement or metastatic disease. It is | recommended only if the conditions in the managed access agreement are followed. | | (NHS England Cancer Drug Fund) | NICE TA581 Nivolumab with ipilimumab is recommended for use within the Cancer Drugs Fund as an option for adults | with untreated advanced renal cell carcinoma that is intermediate - or poor- risk as defined in the I | nternational Metastatic Renal cell carcinoma Database Consortium Criteria. It is recommended only if the | conditions in the managed access agreement for nivolumab with ipilimumab are followed. | | (NHS England Cancer Drug Fund) | | RED Obinutuzumab - recommended as an option for untreated advanced follicular lymphoma as per NICE TA513 | (NHS England Commissioned) | |
|
| RED Olaparib [Lyparza] | NICE TA381 Recommended as an option by NICE for maintenance treatment of relapsed, platinum-sensitive, BRCA | mutation positive ovarian, fallopian tube and peritoneal cancer after response to second-line or | subsequent platinum-based chemotherapy, | NICE TA620 Recommended as an option for the maintenance treatment of relapsed, platinum-sensitive, high grade | epithelial ovarian, fallopian tube or primary peritoneal cancer in adults whose disease has responded to | platinum-based chemotherapy only if: | > they have a BRCA1 or BRCA2 mutation | > they have had 3 or more courses of platinum-based chemotherapy and | > the company provides olaparib according to the commercial arrangement | |
(NHS England Cancer Drug Fund) |
|
RED Olaratumab, solution for infusion, in combination with doxorubicin is recommended as an option for advanced soft tissue sarcoma in adults as per NICE TA465 *June 2019 - see MHRA Drug Safety Update |
(NHS England Commissioned) |
RED Osimertinib [Tagrisso] | NICE TA653 Recommended as an option for treating epidermal growth factor receptor T790M mutation-positive | locally advanced or metastatic non-small-cell lung cancer in adults only if: | > their disease has progressed after first-line treatment with an EGFR tyrosine kinase inhibitor and | > the company provides osimertinib according to the commercial arrangement | [Replaces NICE TA416] (NHS England Commissioned ) | | NICE TA654 Recommended within its marketing authorisation, as an option for untreated locally advanced or | metastatic epidermal growth factor receptor mutation-positive non-small-cell lung cancer in adults. | [Replaces NICE TA621] (NHS England Commissioned ) | | |
RED Oxaliplatin injection 50mg, 100mg (NICE indication only) RED Paclitaxel injection 30mg/5ml (NICE indication only) |
RED Paclitaxel Iv infusion - in combination with platinum as an option for treating recurrent ovarian cancer |
in - NICE TA389 |
RED Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer | - an option by NICE TA476 (replaces TA360) | RED Palbociclib - with an aromatase inhibitor, is recommended within its marketing authroisation, as an option | for treating hormone receptor-positive , human epidermal growth receptor 2-negative, locally advanced | or metastatic breast cancer as initial endocrine-based therapy in adults NICE TA495 | RED Palbociclib | NICE TA619 Recommended as an option with fulvestrant for use within the Cancer Drugs Fund for treating hormone | receptor-positive, human epidermai growth factor receptor 2 (HER2) - negative, locally advanced or | metastatic breast cancer in people who have had previous endocrine therapy only if: | > examestane plus everolimus is the most appropriate alternative to a cyclin-dependent kinase 4 and 6 | (CDK 4/6) inhibitor and | > the conditions in the managed access agreement for palbociclib with fulvestrant are followed. | | | | | |
RED Panitumumab is recommended, as an option for previously untreated metastatic colorectal cancer | as per NICE TA 439 (updated Sept 2017) | |
RED Panobinostat 20mg tablets - recommended as an option by NICE for treating multiple myeloma after |
at least two previous treatments. NICE TA380 |
RED Pazopanib Tablets, f/c - recommended as a first-line treatment option for people with advanced renal |
cell carcinoma in NICE TA215 |
RED Pegaspargase as an option for treating acute lymphoblastic leukaemia in children, young people and adults |
only when they have untreated newly diagnosed disease, (as part of antineoplastic combination therapy) in NICE TA408 RED Pembrolizumab as an option for treating locally advanced or metastatic PD-L1-positive non-small-cell lung cancer in adults who have had at least one chemotherapy as per NICE TA428 (NHS England Commissioned) |
RED Pembrolizumab for use within the Cancer Drugs Fund as an option by NICE TA447 for untreated PD-L1- positive metastatic non-small-cell lung cancer in adults | RED Pembrolizumab - recommended as an option for treating locally advanced or metastatic urothelial | carcinoma after platinum-containing chemotherapy as per NICE TA519 | RED Pembrolizumab - recommended for use within the Cancer drugs Fund as an option for untreated locally | advancedor metastatic carcinoma in adults when cisplatin-containing chemotherapy is unsuitable - as | per NICE TA522. (Guidance updated July 2018: The European medicines Agency restricted the use of pembrolizumab for untreated urothelial carcinoma. It should now only be used in adults with high levels | of PD-L1. For more information, see the summary of product characteristics for pembrolizumab). | (NHS England Cancer Drug Fund) | RED Pembrolizumab is recommended for use within the Cancer Drug Fund as an option for the adjuvant | treatment of Stage III melanoma with lymph node involvement in adults who have had complete | resection - as per NICE TA553 (NHS England Cancer Drug Fund) | | | RED Pembrolizumab is recommended as an option for untreated PD-L1 positive metastatic non-small-cell lung | cancer in adults whose tumours express PD-L1 (with at least 50% tumour proportion score) and have no | (replaces NICE TA447) (NHS England Commissioned | RED Pembrolizumab is receommended as an option for treating relapsed or refractory classical Hodgkin | lymphoma in adults who have has brentuximab vedotin and cannot have autologous stem cell | transplant as in NICE TA540 (NHS England Cancer Drug Fund) | RED Pembrolizumab with pemetrexed and platinum chemotherapy is recommended for use within the Cancer Drugs Fund, as an option for untreated, metastatic, non-squamous non-small-cell lung cancer (NSCLC) in | adults whose tumours have no epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-positive mutations. NICE TA557 (NHS England Cancer Drug Fund) | | NICE TA600 Pembrolizumab, with carboplatin and paclitaxel, is recommended for use within the Cancer Drugs Fund as | an option for untreated metastatic squamous non-small-cell lung cancer in adults only if: | > pembrolizumab is stopped at 2 years of uninterrupted treatment, or earlier if disease progresses, and | > the company provides pembrolizumab according to the managed access agreement | NICE TA661 Recommended as an option for untreated metastatic or unresectable recurrent head and neck squamous | cell carcinoma in adults whose tumours express PD-L1 with a combined positive score of 1 or more. | (NHS England Commissioned) | | | | | | | | |
RED Pentostatin injection 10mg |
RED Pertuzumab solution for infusion 30mg/mL - an option for the neoadjuvant treatment of adults with human epidermal growth factor receptor 2 (HER2)‑positive breast cancer, in combination with trastuzumab and chemotherapy, as per NICE TA424 |
RED Pertuzumab HER2-positive metastatic or locally recurrent unrescetable breast cancer in adults who have | not had previous anti‑HER2 therapy or chemotherapy for their metastatic disease (in combination with | trastuzumab and docetaxel - NICE TA509 | RED Pertuzumab - NICE TA569 - Recommended, with intarvenous tarstuzumab and chemotherpay, for the | adjuvant treatment of human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer | in adults, only if: | > they have lymph node-positive disease | > the company provides it according to the commercial arrangement | (NHS England Commissioned) | | | |
RED Ponatinib - Recommended as per NICE TA451 as an option for treating chronic-accelerated -or blast - phase | chronic myeloid leukaemia in adults. (NHS England Commissioned) | |
RED Procarbazine capsules 50mg |
RED Radium-223 dichloride recommended as an option by NICE for treating hormone-relapsed pro state cancer |
with bone metastases. NICE TA376 |
RED Regorafenib recommended as an option for treating unresectable or metastatic gastrointestinal stromal | tumours in adults whose disease has progressed on, or who are intolerant to, prior treatment with | imitinib and sunitinib, as per NICE TA488 (NHS England Commissioned) | RED Regorafenib is recommended as an option in NICE TA555 for treating advanced unrescetable hepatocellular | carcinoma in adults who have had sorafenib, only if: | > they have Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) | performance status of 0 or 1 and | > the company provides it according to the commercial arrangement. (NHS England Commissioned) | | | RED Ribociclib with an aromatase inhibitor, is recommended within its marketing authorisation, as an option | for treating hormone receptor-positive, human epidermal growth factor receptor 2‑negative, locally | advanced or metastatic breast cancer as initial endocrine-based therapy in adults. Ribociclib is | recommended only if the company provides it with the discount agreed in the patient access scheme. RED Ribociclib with an aromatase inhibitor, is recommended within its marketing authorisation, as an option | for treating hormone receptor-positive, human epidermal growth factor receptor 2‑negative, locally | advanced or metastatic breast cancer as initial endocrine-based therapy in adults. Ribociclib is | recommended only if the company provides it with the discount agreed in the patient access scheme. | NICE TA496 | RED Rucaparib | NICE TA611 Recommended for use within the Cancer Drugs Fund as an option for maintenance treatment of | relapsed platinum- sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer | that has responded to platinum-based chemotherapy in adults, only if the conditions in the | | managed access agreement for rucaparib are followed. (NHS England Cancer Drug Fund) | | | | |
RED Ruxolitinib tablets 5mg,10mg.15mg,20mg NICE TA386 |
RED Sorafenib tablets 200mg recommended as an option for treating hepatocellular carcinoma only for people |
with Child-Pugh grade A liver impairment as per NICE TA474 |
RED Sunitinib capsules 12.5mg, 25mg, 50mg RED Sunitinib capsules 12.5mg, 25mg, 50mg recommended as an option treating well- or moderately differentiated unresectable or metastatic neuroendocrine tumours (NETs) of pancreatic origin in adults with progressive disease. NICE TA 449 (NHS England Commissioned) | |
RED Temozolomide capsules 5mg, 20mg, 100mg,140mg, 180mg,250mg NICE TA23 (updated March 2016) |
RED Tisagenlecleucal is recommended for use within the cancer drug fund as an option for treating relapsed or | refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years , as per NICE TA554 | |
(NHS England Cancer Drug Fund) |
RED Tivozanib - an option in advanced renal cell carcinoma in adults as per NICE TA512 |
(NHS England Commissioned) |
RED Topetecan infusion Ovarian cancer (NICE TA91) |
RED Topetecan infusion cervical cancer, recurrent (NHS England Commissioned) |
RED Trabectedin powder for concentrate 0.25mg, 1mg (Yondelis®) as an treatment option for people with |
advanced soft tissue sarcoma as per NICE TA185 |
RED Trametininb tablets 0.5mg, 2mg as an option by NICE for treating unresectable or metastatic melanoma |
in combination with darbrafenib - NICE TA396 |
RED Trastuzumab injection 150mg (NICE indications only) |
combination as per NICE TA458 updated (replaces TA371) (NHS England Cancer Drug Fund) | | RED Trastuzumab emtansine [Kadcyla®] | NICE TA458 Trastuzumab emtansine is recommended, within its marketing authorisation, as an option for treating a | human epidermal growth factor receptor (HER2) - positive, unrescetable, locally advanced or | metastatic breast cancer in adults who previously received trastuzumab and a taxane, separately or in | combination - updated (replaces TA371). (NHS England Cancer Drug Fund) | NICE TA632 Trastuzumab emtansine is recommended, within its marketing authorisation, as an option for the adjuvant | treatment of human epidermal growth g=factor receptor 2 (HER2)- positive early breast cancer in adults | who have had residual invasive disease in the breast or lymph nodes after neoadjuvant taxane-based and | HER2-targeted therapy.It is recommended only if the company provides trastuzumab emtansine | according to the commercial arrangement NHS England Commissioned | | | | |
RED Tretinoin capsules 10mg |
(Consultant haematologist only – use whilst waiting transfer to specialist centre - see relevant protocol) |
RED Trifluridine-tipiracil tablets 15mg, 20mg - as per NICE TA405 |
RED Vemfurafenib tablets 240mg |
RED Venetoclax - as an option within the Cancer Drugs Fund , within its marketing authorisation, for treating | chronic lymphocytic leukaemia as per NICE TA487 | RED Venetoclax with rituximab - recommended, within its marketing authorisation, as an option for treating | chronic lymphocyticleukaemia in adults who have had at least 1 previous therapy. NICE TA561 | | RED Venetoclax [Venclyxto] | NICE TA487 Recommended as an option within the Cancer Drugs Fund, within its marketing authorisation, for treating | chronic lymphocytic leukaemia | NICE TA561 Venetoclax with rituximab - recommended, within its marketing authorisation, as an option for treating | chronic lymphocytic leukaemia in adults who have had at least 1 previous therapy. | (NHS England Cancer Drugs Fund) | NICE TA663 Venetoclax plus obinutuzumab is recommended as an option for untreated chronic lymphocytic | leukaemia [CLL] in adults, only if: | > there is a 17p deletion or TP53 mutation, or | > there is no 17p deletion or TP53 mutation, and fludarabine plus cyclophosphamide and rituximab | [FCR], or bendamustine plus rituximab [BR], is unsuitable, and | > the companies provide the drugs according to the commercial arrangements. | Venetoclax plus obinutuzumab is recommended for use within the Cancer drugs Fund as an option for | untreated CLL in adults, only if: | > there is no 17p deletion or TP53 mutation, and FCR or BR is suitable, and | > the conditions in the managed access agreement for venetoclax plus obinutuxumab are followed | | | | | | | | | | | | | | | | | | |